Alacrita and Debiopharm Group™ Collaborate
News Jun 25, 2013
Alacrita and Debiopharm Group™ (Debiopharm) have established an alliance to identify oncological, autoimmune, infectious diseases as well as metabolic in-licensing opportunities stemming from the Massachusetts life science cluster.
Alacrita will strengthen Debiopharm’s in-house scouting team in their search for small molecules, antibody or peptide-based product candidates.
The companies are seeking preclinical assets against novel targets which represent first-in-class opportunities.
Debiopharm focuses on the development of prescription drugs that target unmet medical needs. The company recently in-licensed assets from two Massachusetts companies, including Mercury Therapeutics Inc. (Woburn, MA) and Curis Inc. (Lexington, MA).
In recognition of the depth and breadth of life science innovation in Massachusetts, Debiopharm sees the value of a local presence in the region and has selected Alacrita as its representative.
Alacrita is also in charge of identifying opportunities for Debiopharm elsewhere on the East Coast.
David Deperthes, Vice President, Business Development & Licensing at Debiopharm said: “Massachusetts hosts global leaders in pharmaceutical innovation. As such, the area represents a strategic priority for us as we source opportunities from around the world to expand our pipeline of novel medicines. We are delighted to be working with Alacrita, a leading pharma consultancy on both sides of the Atlantic.”
Rob Johnson, Partner at Alacrita Consulting, said: “Debiopharm’s resources and expertise in global pharmaceutical development make it an ideal partner for Massachusetts organizations looking to move their preclinical programs into clinical trials. Debiopharm has a track record of shepherding early stage pharmaceutical programs into late stage clinical trials and has demonstrated extraordinary success in delivering new medical breakthroughs to patients, a testament to its impressive preclinical, clinical, manufacturing, drug delivery, formulation and regulatory expertise. Alacrita is proud to have been selected by Debiopharm to source new in-licensing opportunities for the group and enable the next generation of medical products.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE